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CUB-domain-containing protein 1 (CDCP1) is an integral
membraneglycoproteinwithpotential asamarkerandtherapeutic
target for a number of cancers. Herewe examinemechanisms reg-
ulating cellular processingofCDCP1.By analyzing cell lines exclu-
sively passaged non-enzymatically and through use of a panel of
protease inhibitors, we demonstrate that full-length 135 kDa
CDCP1 ispost-translationally processed in a rangeof cell linesby a
mechanism involving serine protease activity, generating a C-ter-
minal 70-kDa fragment. Immunopurification and N-terminal
sequencing of this cell-retained fragment and detailed mutagene-
sis, show that proteolytic processing of CDCP1 occurs at two sites,
Arg-368andLys-369.Weshow that the serineproteasematriptase
is an efficient, but not essential, cellular processor of CDCP1 at
Arg-368. Importantly, we also demonstrate that proteolysis
induces tyrosine phosphorylation of 70-kDa CDCP1 and recruit-
ment of Src and PKC to this fragment. In addition,Western blot
and mass spectroscopy analyses show that an N-terminal 65-kDa
CDCP1ectodomain is shed intact from the cell surface.Thesedata
provide new insights intomechanisms regulatingCDCP1and sug-
gest that thebiological roleof thisproteinand,potentially, its func-
tion in cancer, may be mediated by both 70-kDa cell retained and
65-kDa shed fragments, as well as the full-length 135-kDa protein.
CUB-domain-containing protein 1 (CDCP1)3 is an 836
amino acid integral membrane glycoprotein with a type I ori-
entation at the cell surface (1–4), that is up-regulated in a num-
ber ofmalignancies including breast (1, 5, 6), colon (1, 2, 7), and
lung (1) cancers. Of potential clinical significance, CDCP1
expression correlates with recurrence and patient survival rate
in renal cell carcinomas (8) and lung adenocarcinomas (9), indi-
cating that itmay be suitable as a prognosticmarker. Consistent
with a role in cancer progression, silencing of CDCP1 reduced
the metastatic ability of lung cancer A549 cells (10) and the
peritoneal dissemination of gastric cancer 44As3 cells (11) in
mice. Although its biological function is not known, the poten-
tial of CDCP1 as a therapeutic target for cancer treatment has
been highlighted by studies showing that antibody-mediated
inhibition of CDCP1 reducedmetastasis of prostate cancer PC3
cells in mice (12, 13) and chicken embryos (13). Currently the
mechanisms regulating CDCP1 in cancer and normal physiol-
ogy are not well defined (14).
During cellular processing, the 29-residue CDCP1 N-termi-
nal signal peptide is removed generating a protein with molec-
ular mass identified as either 135 kDa (2, 10, 15) or 140 kDa (3,
4) that contains 30–40 kDa ofN-linked glycans (2). In addition
to this full-length form, there is evidence that a shorter CDCP1
species is expressed endogenously by a range of cell lines or is
generated through the action of exogenous serine proteases.
For example, lung cancer A549, PC14, H520, H322, and H157
cells (10) and gastric cancer 44As3 and 58As9 cells (11) resus-
pended non-enzymatically using a metal ion chelator (EDTA)
to disrupt cell/matrix interactions, express CDCP1 as the full-
length protein as well as a shorter species with a reported
molecular mass of 70 kDa. Similarly, colon HCT116 and
DLD-1, pancreatic MiaPaCa2 and prostate cancer PC3 cells
resuspendedwith EDTA express a shorter form of CDCP1with
a reported molecular mass of 85 kDa (16). Interestingly, exog-
enous serine proteases also generate short CDCP1 species that
have different reported molecular weights. For example, the
serine protease trypsin generates a CDCP1 fragment in human
foreskin keratinoytes (3) and breast MCF10A cells (17) with
reported molecular masses of 80 kDa and 85 kDa, respectively,
while another serine protease, plasmin, generates a reported
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80-kDa CDCP1 protein in cultured keratinocytes (3). Signifi-
cantly, the observation that 80 kDa and full-length CDCP1 are
expressed in untreated preparations of neonatal mouse epider-
mis (3), suggests that mechanisms generating short forms of
CDCP1 occur in vivo and that it will be important to under-
stand the mechanisms controlling the generation of these
species.
Here we examine the expression of full-length and lower
molecular weight CDCP1 in cell lines originating from five dif-
ferent tissues focusing on prostate-derived cells to demonstrate
that endogenous lower molecular weight CDCP1 is generated
though the action of serine proteases. We also examine the
ability of the type II transmembrane serine protease (TTSP)
matriptase (18) to proteolytically process and induce tyrosine
phosphorylation of CDCP1. Importantly, we analyze down-
streamconsequences ofCDCP1 cleavage showing that it results
in shedding of a 65-kDaCDCP1 ectodomain and tyrosine phos-
phorylation of cell-retained 70-kDa CDCP1 and recruitment of
Src and PKC to this fragment. Our data indicate that it will be
important to better understand the molecular regulators and
downstream signaling events coupled to normal and dysregu-
lated CDCP1 processing.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Antibodies were from the follow-
ing suppliers: goat polyclonal antibody against the last 13C-ter-
minal residues of CDCP1 from Abcam (Cambridge, MA;
ab1377); rabbit polyclonal antibody against unspecified C-ter-
minal residues of CDCP1 from Cell Signaling Technology (CST;
Danvers, MA; 4115); goat antibody against the extracellular
domain of CDCP1 from R&D Systems (Bio-Scientific Pty Ltd,
Gymea, Australia; AF2666); rabbit anti-matriptase antibody from
Bethyl Laboratories (Montgomery, TX); rabbit anti-Src antibody
fromCST(2108); rabbit anti-PKCantibody fromSantaCruzBio-
technology (Santa Cruz, CA; SC-937); rabbit anti-p-FAK-Y861
antibody that detects both p-CDCP1-Y734 and p-FAK-Y861 (3),
from Invitrogen (Mulgrave, Australia); rabbit and mouse mono-
clonal anti-Flag epitope (DYKDDDDK) antibodies from Sigma;
monoclonal anti-phosphotyrosine antibody PY20 from Calbio-
chem (La Jolla, CA); monoclonal anti-glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) antibody from Chemicon Inter-
national (Boronia, Australia); and HRP-conjugated secondary
antibodies from Thermo Scientific (Murarrie, Australia). Control
immunoglobulins (IgGs) were from Sigma and Invitrogen. The
protease inhibitors aprotinin, phenylmethylsulfonyl fluoride
(PMSF), tosyl-L-phenylalanine chloromethyl ketone (TPCK),
tosyl-L-lysinechloromethylketone (TLCK), and (R)-N4-hydroxy-
N1-[(S)-2-(1H-indol-3-yl)-1-methylcarbamoyl-ethyl]-2-isobu-
tyl-succinamide (GM6001), leupeptin, pepstatin, and trans-ep-
oxysuccinyl-l-leucylamido-(4-guanidino)butane (E-64) were
from Sigma. Protein A/G-agarose and Complete EDTA-free
protease inhibitor were from Roche Applied Sciences (Castle
Hill, Australia). Blasticidin was from InvivoGen (San Diego,
CA). Precision Plus Protein Dual Color Standard (catalogue
number 161-0374) was from Bio-Rad. All other chemicals were
from Sigma.
Expression Constructs—CDCP1-encoding cDNA was re-
verse transcribed from total RNA extracted from PC3 cells and
amplified using Expand high fidelity polymerase (Roche
Applied Science), and inserted into pcDNA3.1 vector (Invitro-
gen) generating an expression construct encoding full-length
CDCP1 with a cytoplasmic, C-terminal Flag epitope. A
matriptase-encoding expression construct has been described
previously (19). Site-directed mutagenesis, to introduce
CDCP1mutations R362A, K365A, R368A, K369A, and F370W,
and a stop codon replacing Lys-369 or Phe-370, was performed
using Pfu Ultra polymerase (Stratagene, La Jolla, CA). The
sequence of all constructs was confirmed by DNA sequenc-
ing at the Australian Genome Research Facility (St. Lucia,
Australia).
Cell Culture andTransfections—Cells used in this studywere
purchased from the American Type Culture Collection. HeLa
cells stably transfected with either pcDNA3.1 (vector) or the
CDCP1-Flag expression construct were described previously
(13). Prostate cancer lines PC3, LNCaP, DU145, 22Rv1, and
immortalized prostate cell lines RWPE-1 and RWPE-2 and
lymphoid K562, U937, Jurkat, and YT cells were grown in
RPMI1640 medium, and cervical Ca Ski and HeLa cells, breast
cell lines MDA-MB-231, MDA-MB-468, and Hs578t in Dul-
becco’s modified Eagle’s medium. Breast MCF7 and MCF10A
cells were grown in MEM and DMEM/F12 media, respec-
tively, containing insulin (10 g/ml). Cultures were supple-
mented with 10% fetal calf serum, 100 units/ml of penicillin,
and 100 units/ml of streptomycin unless otherwise specified
and incubated at 37 °C in 5% CO2. Unless otherwise specified,
all cells were passaged using 0.5 mM EDTA in PBS. In medium-
exchanging experiments, donor cells were cultured in serum-
containing medium for 3 days before the medium was col-
lected, spun at 800 g for 5 min, and the cell-free supernatant
applied to acceptor cells, which had been cultured for 1–2 days
to50% confluence. In experiments to assess the class of pro-
tease mediating CDCP1 processing, immediately before trans-
fer to CDCP1-expressing cells, serum containing conditioned
mediumwas supplemented with Complete (EDTA-free) inhib-
itor mixture, PMSF, aprotinin, TLCK, TPCK, leupeptin,
GM6001, pepstatin, or E-64 at the concentrations specified in
the relevant figure legend. Cell transfections were performed
using Lipofectamine 2000 (Invitrogen), following the instruc-
tions of the manufacturer.
Immunoprecipitation—In experiments to detect interacting
proteins, cell lysates were collected in either PBS (pH 7.4) con-
taining 1% CHAPS (Sigma) or 10 mM Tris-HCl (pH 7.4) con-
taining 150 mM NaCl, 1% Triton X-100, in the presence of 1
protease inhibitor mixture, 2 mM sodium vanadate and 10 mM
sodium fluoride. In experiments to purify low and high molec-
ular weight CDCP1, cells were lysed in a buffer containing 1%
SDS, 2 mM DTT, and protease inhibitor mixture followed by
denaturation at 100 °C for 5min. Thismixture was then diluted
10-fold in buffer containing 0.55% IGEPAL, 55.55 mM Tris (pH
8.0), 11.1 mMMgCl2, and protease inhibitor mixture. In exper-
iments to characterize the shed ectodomain of CDCP1, immu-
noprecipitation was performed from conditioned medium.
DU145 cells were cultured in serum-free medium for 3 days.
Themediumwas then centrifuged briefly to remove intact cells,
and proteins were recovered by acetone precipitation. Lysates
andmedia were pre-clearedwith proteinA/G-agarose for 1 h at
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4 °C on a rolling platform. After centrifugation, the supernatant
was mixed with appropriate antibodies or isotype IgGs and
incubated overnight at 4 °C. Fresh aliquots of protein A/G-aga-
rose beads were then added, and the mixture was incubated for
4 h at 4 °C with gentle agitation. The beads were then washed
three times in cell lysis buffer. Associated proteins were eluted
into Laemmli sample buffer and subjected to SDS-PAGE fol-
lowed by either Western blot analysis, Edman degradation
sequencing, or mass spectroscopy analysis.
Western Blot Analysis—Whole cell lysates were collected in a
buffer containing protease inhibitor mixture, 2 mM sodium
vanadate, and 10 mM sodium fluoride and either Triton X-100
(1%), 50 mM Tris-HCl (pH 7.4), and NaCl (150 mM), or CHAPS
(1%), PBS (pH 7.4), and MgCl2 (2 mM). Protein concentrations
were determined by a microbicinchoninic acid assay (Thermo
Scientific). Proteins from serum-free conditioned medium
from cells cultured for 3 days (300 l) were concentrated by
acetone precipitation then resuspended in lysis buffer (20 l).
Cell lysates, acetone-precipitated proteins from conditioned
medium and immunoprecipitated proteins were separated by
SDS-PAGEunder reducing conditions and transferred to nitro-
cellulose membranes, which were blocked in 5% skim milk in
Tris-buffered saline containing 0.1% Tween 20 (TBS-T). Mem-
branes were incubated with appropriate antibodies diluted in
blocking buffer for 1 h at room temperature, washed with
TBS-T, and then incubatedwith species-appropriateHRP-con-
jugated secondary antibodies for 45 min. Following washes,
membranes were incubated with SuperSignal West Pico
Substrate (Pierce) and then exposed to film. Consistent pro-
tein loading and transfer was determined by reprobingmem-
branes stripped in Restore Western blot stripping buffer
(Pierce) with anti-matriptase, anti-GAPDH, or anti-Flag
antibodies as appropriate.
EdmanDegradation Protein Sequencing—N-terminal sequenc-
ing of immunopurified CDCP1 electrophoretically transferred to
PVDFmembranes was carried out on an Applied Biosystems 494
Procise Protein Sequencing System at the Australian Proteome
Analysis Facility (Macquarie University, Sydney, Australia).
Mass Spectroscopy Analysis—The protein band of interest
from a Coomassie-stained gel was excised and subjected to
reduction, acetylation, and trypsin digestion. Fragments were
resolved by liquid chromatography and analyzed on a QStar
Elite quadrupole-time-of-flight mass spectrometer (Applied
Biosystems). Data were analyzed using the Paragon algorithm
as part of the ProteinPilot software package (Applied Biosys-
tems) and searched against the current version of the SwisProt/
UniProt database.
Matriptase Treatment of Cells—Generation and character-
ization of recombinantmatriptase serine protease domain used
in this study has been described previously (20). Cells were
allowed to attach for 12 h in serum-containing medium, then
starved of serum for 24hbefore beingwashedwith fresh serum-
free medium. Another aliquot of serum-free medium contain-
ing matriptase (1, 5, or 10 nM) was then added, and the cells
were incubated for 1, 5, 10, or 30 min before being lysed for
Western blot analysis as described above. The concentration to
stimulate half-maximal processing (EC50) was determined
from anti-CDCP1 Western blot analysis of three independent
experiments by plotting percentage CDCP1 conversion versus
matriptase concentration for the 30 min time point. In experi-
ments to assess changes in phosphorylation of CDCP1 due to
matriptase treatment, 22Rv1 cells were either untreated or
treated with matriptase (20 nM) for 0.5, 1, or 2 h. Immunopre-
cipitation was then performed on the collected lysates using
either a rabbit anti-CDCP1 antibody or control rabbit IgGs fol-
lowed by mouse anti-phosphotyrosine Western blot analysis.
The blot was reprobed with anti-rabbit secondary antibody to
confirm consistency in the amount of antibody used in the
immunoprecipitation.
Reduction ofMatriptase Expression—Matriptase activity was
reduced by silencing of expression. Polyclonal populations of
PC3 and DU145 cells with stable suppression of matriptase
expression were generated using four constructs generated
in a BLOCK-iT Pol II miR RNAi expression vector backbone
and containing sequences selected using the Invitrogen
Block-iT miR RNAi Select tool (CCAACATTGACTGCAC-
ATGGA, GCCCAACAACCAGCATGTGAA, GTACACA-
AGGCTCCCTCTGTT, and TCCTGCCAGTCAACAACG-
TCA). Constructs containing either scrambled (GTCTCCA-
CGCGCAGTACATTT) or LacZ-targeting (GACTACACA-
AATCAGCGATTT) sequences from Invitrogen were used as
controls. Cells were selected in medium containing blasticidin
(InvivoGen, San Diego, CA) at a concentration of 3 and 10
g/ml for PC3 and DU145 cells, respectively, for 4 weeks. Sup-
pression of matriptase expression and effect on CDCP1 proc-
essing was assessed by Western blot analysis.
RESULTS
Post-translational Processing of 135-kDaCDCP1Generates a
70 kDa protein—To examine the expression of CDCP1 in
human cell lines,Western blot analysis was performed using an
antibody generated against a peptide encompassing the last 13
amino acids of CDCP1 (residues 824–836 of GenBankTM entry
AAO33397). To ensure that passaging of cells using trypsin did
not contribute to generation of lowermolecular weight CDCP1
species, analysis was performed on cells that had been passaged
exclusively using EDTA (0.5 mM). As shown in Fig. 1A, CDCP1
was detected in 14 of the 19 analyzed cell lines. Of these 14
CDCP1-expressing lines, 9 clearly expressed twoCDCP1 forms
of 70 and 135 kDa, PC3, LNCaP, and DU145 prostate cells, Ca
Ski cervical cells, Hs578t, MDA-MB-231, and MDA-MB-468
breast cells, and K562 and U937 lymphoid cells. In addition, on
longer exposure prostate cancer 22Rv1 and breast cancer T47D
cells showed low level expression of the 70-kDa band. CDCP1
was not detected in cervical HeLa, breast MCF7, or lymphoid
Jurkat and YT cells.
Previous studies have reported lower molecular mass
CDCP1of 70, 80, or 85 kDa, generated either through the action
of exogenous trypsin and plasmin (3, 17) or unknown mecha-
nisms (11, 16). To examine the relationship between these spe-
cies and endogenous 70 kDa CDCP1 detected in Fig. 1A, we
used anti-CDCP1 Western blot analysis to compare lysates
from cells that predominantly express only 135 kDa CDCP1
(prostate 22Rv1 cells) with lysates obtained from the same line
after a single treatment with trypsin (0.25% solution). Lysates
from a cell line that expresses both 70 and 135 kDa CDCP1
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(PC3 cells) were used to compare endogenous 70 kDa CDCP1
and the trypsin-induced species. As shown in Fig. 1B, lower
molecular weight CDCP1 produced in 22Rv1 cells by trypsin
treatment migrated at the same molecular mass as the 70-kDa
CDCP1 band expressed endogenously by PC3 cells. These data
suggest that cleavage by the serine protease trypsin generates a
CDCP1 species of the same molecular weight as produced
endogenously by a range of cell lines (Fig. 1A).
To examine the mechanism by which 70 kDa CDCP1 is gen-
erated, we transiently transfected prostate PC3 and 22Rv1 cells
with a construct encoding full-length CDCP1 with a cytoplas-
mic, C-terminal Flag epitope (CDCP1-Flag). We have shown
that PC3 cells endogenously express both 70 and 135 kDa
CDCP1 whereas 22Rv1 cells predominantly express only high
molecular weight CDCP1 (Fig. 1A). As shown in Fig. 1C (left
panel), Western blot analysis using an anti-Flag antibody indi-
cated that PC3 cells began to express 135 and 70 kDa CDCP1-
Flag, 8 and 24 h after transfection, respectively. As CDCP1-Flag
expressed by these cells is generated fromplasmidDNA encod-
ing only the full-length protein, 70 kDa CDCP1-Flag must have
been produced through a post-translational processing event
rather than via alternate processing of a pre-mRNA transcript.
Consistent with this proposal, anti-Flag Western blot analysis
of lysates from 22Rv1 cells transiently transfected with the
CDCP1-Flag construct detected only 135 kDa CDCP1-Flag
(Fig. 1C, right panel).
To assess whether CDCP1 processing is mediated by a cell
secreted or shed factor or factors, 22Rv1 and HeLa cells stably
expressing CDCP1-Flag (designated HeLa-CDCP1-Flag (13)),
which are low and non-CDCP1-processing cell lines, respec-
tively, were cultured either in stan-
dard medium or conditioned
medium from CDCP1-processing
PC3 cells. As shown in Fig. 1D (left
panel), anti-CDCP1 Western blot
analysis indicated that PC3-condi-
tioned medium contains a factor
that enables processing of 135 kDa
CDCP1 to 70 kDa in 22Rv1 cells.
The same result was obtained from
anti-Flag Western blot analysis of
lysates from HeLa-CDCP1-Flag
cells treated in the same way (Fig.
1D, right panel). These data indicate
that CDCP1 processing is mediated
by a cell-secreted or shed factor or
factors.
Serine Protease Activity Is Re-
quired for Cellular Conversion of
135 kDa CDCP1 to 70 kDa—To ex-
amine whether endogenous CDCP1
processing is mediated by a
protease, we performed experi-
ments in which PC3 cell-condi-
tioned medium was treated with
various protease inhibitors includ-
ing a broad range mixture targeting
serine, cysteine, and metallopro-
teases as well as inhibitors of narrower specificity: phenylmeth-
ylsulfonyl fluoride (21), aprotinin (22–24), TLCK (25), and
TPCK (26) (serine protease inhibitors); leupeptin (mixed ser-
ine/cysteine protease inhibitor (27)); GM6001 (matrix metallo-
protease inhibitor (28, 29)); pepstatin (aspartyl protease inhib-
itor (30)); and E-64 (cysteine protease inhibitor (31)). We
incubated HeLa-CDCP1-Flag cells with either untreated or
protease inhibitor-treated PC3-conditioned medium for 24 h
and analyzed cell lysates byWestern blot analysis using an anti-
Flag antibody. The protease inhibitor mixture was effective at
completely blocking PC3media-induced proteolysis of CDCP1
suggesting the involvement of serine, cysteine and/or metallo-
proteases in processing (Fig. 2A). Use of protease inhibitors of
narrower specificity indicated that CDCP1 processing is
blocked by the serine protease inhibitors PMSF (at intermedi-
ate to high concentration) and aprotinin (at low to intermediate
concentration) (Fig. 2B), and the mixed serine/cysteine prote-
ase inhibitor leupeptin (at high concentration) (Fig. 2C), but not
by the serine protease inhibitors TPCK and TLCK (Fig. 2B), the
matrix metalloprotease inhibitor GM6001 (Fig. 2D), the aspar-
tyl protease inhibitor pepstatin (Fig. 2E), or the cysteine prote-
ase inhibitor E-64 (Fig. 2F). Although at concentrations greater
than 25 M, GM6001 reduced the level of 70 kDa CDCP1, this
was accompanied by a similar reduction in expression of 135
kDa CDCP1, likely indicating its effect was to down-regulate
expression rather than proteolytic processing of CDCP1. These
data suggest that cellular processing of CDCP1 is mediated by
secreted or shed serine protease activity. This is supported by a
recent report showing that 7 M ecotin, a trypsin-fold-specific
macromolecular serine protease inhibitor, reduces processing
FIGURE 1. Post-translational processing generates 70 kDa CDCP1 from the full-length 135 kDa protein.
A, Western blot analysis using a goat antibody generated against the last 13 C-terminal residues of CDCP1
(Abcamab1377)was performedon lysates from the indicated cell lines passagedwith EDTA. B, trypsin induces
the generation of 70 kDa CDCP1. Lysates from prostate cancer PC3 cells passaged with EDTA and 22Rv1 cells
treated once with either EDTA or trypsin (5 min) were examined by Western blot analysis using a goat anti-
CDCP1 antibody (Abcam ab1377). C, prostate cancer PC3 and 22Rv1 cells were transiently transfected with a
CDCP1-Flag expression construct, and lysateswere collected at the indicated timepoints for anti-FlagWestern
blot analysis.D, Western blot analysis of lysates from 22Rv1 (left panel) and HeLa-CDCP1-Flag (right panel) cells
either untreated or cultured for 24 h in PC3 cell-conditioned medium. Lysates from 22Rv1 cells were probed
with a goat anti-CDCP1 antibody (Abcam ab1377) and lysates fromHeLa-CDCP1-Flag cells were probedwith a
rabbit anti-Flag antibody. Anti-GAPDHWestern blot analysis was performed to examine protein loading.
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of CDCP1 in MDA-MB-468 cells stably overexpressing this
protein (4).
Cellular Proteolytic Processing of CDCP1 Occurs at Arg-368
and Lys-369—To identify the sites at which CDCP1 processing
occurs, we performed immunopurification from HeLa-
CDCP1-Flag cells treated with PC3 cell-conditioned medium
using amouse anti-Flag antibody. As shown in Fig. 3A,Western
blot analysis indicated that this approach immunoprecipitated
both 70 and 135 kDa CDCP1. When performed on a larger
scale, quantities sufficient for amino-terminal sequencing of
both CDCP1 forms were obtained (Fig. 3B). Edman degrada-
tion sequence analysis identified three N-terminal sequences:
30FEIALP, 369KFVPGC, and 370FVPGC. The first of these has
previously been reported by us as the amino-terminal of 135
kDa CDCP1 (2), generated through removal of the 29 residue
signal peptide (Fig. 3B). The other two N-terminal sequences
indicated proteolytic processing of CDCP1 occurs following
Arg-368 and Lys-369. The ratio of the signals obtained from
the N termini commencing at Lys-369 and Phe-370 was 5:1
(Fig. 3B).
To examine whether Arg-368 and Lys-369 are relevant pro-
teolysis sites in cells endogenously expressing CDCP1, we
mutated these and nearby residues by site-directed mutagene-
sis of the CDCP1-Flag expression construct. The following
amino acid substitutions were introduced: single amino acid
changes R362A, K365A, R368A, K369A, F370W; double amino
acid changes R368A/K369A, K369A/F370W; and triple amino
acid change R368A/K369A/F370W (Fig. 4A). When consider-
ing proteolytic processing at Arg-368, residues Arg-362, Lys-
365, Arg-368, Lys-369, and Phe-370
are located in the P7, P4, P1, P1, and
P2 positions, respectively (number-
ing of substrate residues from
Schechter and Berger (32)). For
cleavage at Lys-369, amino acids
Arg-362, Lys-365, Arg-368, Lys-
369, and Phe-370 are located in the
P8, P5, P2, P1, and P1 positions,
respectively.
Experiments were performed by
transiently transfecting wild-type
and mutant CDCP1-Flag expres-
sion constructs into two cell lines
that endogenously express both 70
and 135 kDa CDCP1 (PC3 and
DU145). Lysates from these cells
were examined by anti-Flag West-
ern blot analysis and representative
images and graphical representa-
tions of data averaged from three
experiments are shown in Fig. 4, B
and C. As shown in these panels
(lanes 9 and 11), it was only when
transfections were performed with
the R368A/K369A double and
R368A/K369A/F370W triple mu-
tant constructs that proteolytic
processing generating 70 kDa
CDCP1 was completely blocked in both PC3 and DU145 cells.
These data confirm the existence of two cleavage sites for
CDCP1 in PC3 and DU145 cells at Arg-368 and Lys-369, con-
sistent with our N-terminal sequence data showing that
CDCP1 is proteolytically processed at these two sites (Fig. 3B).
In addition, transfection with the single mutant K369A con-
struct resulted in a reduction in CDCP1 processing at Arg-368
of50% in both cell types (Fig. 4, B andC, lane 7). Also of note,
transfection with the R369A/F370W double mutant construct
resulted in reduction in CDCP1 processing at R368 in PC3 and
DU145 cells of90 and 75%, respectively (Fig. 4, B and C, lane
10). These reductions in processing indicate that for cleavage at
Arg-368, the residues located in the P1 (Lys-369) and P2 (Phe-
370) positions are important. Interestingly, in both cell types
processing at Lys-369 was more than doubled by mutation of
Arg-368 to alanine (Fig. 4, B and C, lane 6) suggesting that the
P2 position is important for processing at this lysine. Alto-
gether, these data confirm Arg-368 and Lys-369 as cellular
processing sites of CDCP1 and indicate that cleavage at each
site is impacted upon differently by nearby residues, suggesting
the likelihood that cleavage at these sites is mediated by differ-
ent serine proteases.
The CDCP1 Ectodomain Is Shed Intact from the Cell Surface—
The next experiments aimed to examine the consequences of
proteolytic processing on the N-terminal of CDCP1. This
required an antibody capable of detecting the N-terminal frag-
ment of CDCP1. As shown in Fig. 5A, a goat antibody generated
against the CDCP1 extracellular domain detected 135 kDa but
not 70 kDa CDCP1 in lysates from the same prostate cell lines
FIGURE 2. Serine protease activity is required for conversion of 135 kDa CDCP1 to 70 kDa. Anti-Flag
Western blot analysis of lysates from HeLa-CDCP1-Flag cells untreated or cultured for 24 h in PC3 cell-condi-
tioned medium that was either untreated or had been supplemented with (A) Complete EDTA-free protease
inhibitor mixture or (B) PMSF, aprotinin, TLCK, or TPCK, (C) leupeptinin, (D) GM6001, (E) pepstatin, or (F) E-64 at
the indicated concentrations. Arrows indicate 70 and 135 kDa CDCP1. Anti-GAPDH Western blot analysis was
performed to examine protein loading.
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examined in Fig. 1A, indicating that the epitope recognized by
this antibody is indeed locatedwithin theN-terminal portion of
CDCP1 that is shed after proteolysis and not in the cell-retained
C-terminal fragment. Using this antibody to analyze condi-
tioned media from these cells indicated that a CDCP1 ectodo-
main of 65 kDa is present at highest levels in DU145-condi-
tioned medium, at medium levels in PC3 and at low and barely
detectable levels, respectively, in LNCaP and 22Rv1-condi-
tioned medium, with no CDCP1 ectodomain present in the
conditioned medium of RWPE1 and RWPE2 cells (Fig. 5B). To
confirm that the antibody actually detected CDCP1, we used it
to perform an immunoprecipitation from the conditioned
medium of DU145 cells and analyzed the purified 65 kDa frag-
ment by mass spectroscopy. This analysis identified a 12-resi-
due tryptic fragment, LEDKQPGNMAGN, that matched
exactly CDCP1 amino acids 297–308. In addition, this antibody
specifically detected only a protein of 65 kDa in the conditioned
medium of HeLa cells transiently transfected with expression
constructs encoding CDCP1 truncated after either Arg-368 or
Lys-369, the identified cleavage sites (Fig. 5C). These data indi-
cate that the CDCP1 ectodomain is shed intact from the cell
surface as a fragment of 65 kDa.
The Serine Protease Matriptase Is an Efficient but Not Essen-
tial Cellular Processor of CDCP1—It has previously been
reported that CDCP1 can be cleaved at Arg-368 by the serine
protease matriptase (4). These in vitro experiments were per-
formed using the purified re-
combinant extracellular domain of
CDCP1 and the purified recombi-
nant catalytic domain ofmatriptase,
and thus provided limited insight as
to whether cleavage would occur
in a cellular setting. To examine
whether matriptase is able to proc-
ess cell expressed CDCP1, HeLa-
CDCP1-Flag cells, which express
only 135 kDa CDCP1, and prostate
22Rv1 cells, which predominantly
express only this CDCP1 species,
were incubated with increasing
concentrations of recombinant mat-
riptase protease domain over 1, 5,
10, and 30 min. Significantly, low
concentrations of matriptase were
able to completely process CDCP1
to 70 kDa in stable overexpressing
(Fig. 6A) and endogenously express-
ing (Fig. 6B) cells within 30minwith
an EC50 of 4.0  1.8 nM in HeLa-
CDCP1-Flag cells.
To identify the site of matriptase
cleavage of cell-expressed CDCP1,
HeLa cells were transiently co-
transfected with a matriptase en-
coding expression construct and
either a wild-type CDCP1 construct
or a construct encoding one of the
single, double, or triple CDCP1
mutants described above. As matriptase is a type II transmem-
brane serine protease that can also be post-translationally shed
from the cell surface (33), transfectionswere performedwith an
expression construct encoding the full-length protein. Anti-
Flag Western blot analysis showed that of the single mutations
only R368A abolished processing, indicating that matriptase
cleaves CDCP1 at Arg-368 but not at nearby arginine or lysine
residues including Lys-369 shown by us to be a site at which
CDCP1 is endogenously proteolytically cleaved in PC3 and
DU145 cells (Fig. 6C).
To directly examine whether matriptase is a cellular proces-
sor of CDCP1, we generated PC3 and DU145 cells in which
matriptase expression had been stably reduced using 4 different
silencing constructs. Anti-matriptase Western blot analysis of
stable polyclonal PC3 cell populations showed that two of the
constructs (miRNA-3 and -4) reducedmatriptase expression by
90% while the two remaining constructs (miRNA-1 and -2)
reduced matriptase expression by 50% (Fig. 6D, left panel).
However, anti-CDCP1 Western blot analysis failed to detect a
consistent change in the levels of 70 kDa CDCP1 (Fig. 6D, left
panel). Similarly with DU145 cells, reduction of matriptase
expression had no impact on CDCP1 proteolysis (Fig. 6D, right
panel). These data indicate either that matriptase does not pro-
teolytically process CDCP1 in PC3 and DU145 cells or that this
protease is one of at least two that cleaves CDCP1 at Arg-368 or
Lys-369.
FIGURE 3. Identification of the sites atwhich CDCP1 is proteolytically processed. A, anti-FlagWestern blot
analysis of proteins obtained from mouse IgG and anti-Flag antibody immunoprecipitations from lysates of
HeLa-CDCP1-Flag cells treated with PC3 cell-conditioned medium. B, Coomassie-stained PVDF membrane of
anti-Flag immunoprecipitates obtained fromHeLa-CDCP1-Flag cells either untreated or treated with PC3 cell-
conditioned medium. To the right is shown the N-terminal sequence obtained by Edman degradation
sequencingof 70 and135 kDaCDCP1andadiagramshowing the locationof the identifiedN terminiwithin the
CDCP1 structure. The data indicated that 135 kDaCDCP1 is processed after Arg-368 and Lys-369 in the ratio 5:1
in a region located between CUB-like domains 1 and 2 (CUB-L1 andCUB-L2). SP, signal peptide; TM, transmem-
brane domain.
Proteolytic Processing of CDCP1
AUGUST 20, 2010•VOLUME 285•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26167
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ProteolysisMediatesTyrosinePhos-
phorylation of 70 kDa CDCP1 and
Binding of Src and PKC—It has
previously been reported that
CDCP1 is a substrate of Src family
kinases (SFKs) (2, 3, 15) and that
trypsin-mediated cell de-adhesion
results in phosphorylation of
CDCP1-Y734 andphosphorylation-
dependent binding of the kinases
Src and PKC (3). We therefore
examined the effect of proteolysis,
independent of cell de-adhesion, on
these processes. First, interactions
between CDCP1, Src, and PKC
were examined in adherent DU145
cells (a cell line that expresses high
levels of 70 kDa CDCP1) by
performing immunoprecipitations
with anti-CDCP1 and anti-Src anti-
bodies from lysates prepared in the
presence and absence of the phos-
phatase inhibitors sodium vanadate
and sodium fluoride.
As shown in Fig. 7A, Western blot
analysis of immunoprecipitations
performed with an anti-CDCP1 anti-
body, demonstrated that CDCP1
binds Src and PKC in adherent
DU145 cells. In the absence of phos-
phatase inhibitors binding was abol-
ished confirming that formation of
the CDCP1SrcPKC complex is
phosphorylation-dependent (10, 15). Interestingly, Western blot
analysis with an antibody that detects both p-CDCP1-Y734 and
p-FAK-Y861 (3), indicated that 70 kDa but not 135 kDa
CDCP1-Y734 is phosphorylated in these cells (Fig. 7A, second
bottom panel). Importantly, analysis of these immunoprecipi-
tates with an anti-CDCP1 antibody indicated that both 70 and
135 kDa CDCP1 were efficiently immunoprecipitated in these
experiments (Fig. 7A, lower panel).
Several interesting observations were made from Western
blot analyses of immunoprecipitations performed with an
anti-Src antibody. In addition to supporting the existence of a
phosphorylation-dependent CDCP1SrcPKC complex in
adherent DU145 cells (Fig. 7B), these analyses showed that Src
binds almost exclusively to 70 kDa CDCP1 (Fig. 7B, upper
panel). In addition, analysis with the antibody that detects both
p-CDCP1-Y734 and p-FAK-Y861 (3), demonstrated that Src-
bound 70 kDa CDCP1 is phosphorylated on Tyr-734 (Fig. 7B,
second panel from top). Consistent with a previous report (34),
p-FAK-Y861 co-immunoprecipitated with Src (Fig. 7B, second
panel from top). However, based on the data shown in Fig. 7A
(second bottompanel), p-FAK-Y861 is not present in the 70 kDa
CDCP1SrcPKC complex.
Together the data in Fig. 7, A and B suggest that phosphory-
lated 70 kDaCDCP1-Y734 forms a complex with Src and PKC
in DU145 cells. However, it is not yet known whether proteol-
FIGURE 4. Examination of the cellular proteolytic processing sites of CDCP1. A, schematic showing the
location of single, double, and triple amino acid mutations introduced into the CDCP1-Flag sequence between
CUB-likedomain1and2 (CUB-L1andCUB-L2), R362A, K365A, R368A, K369A, F370W,R368A-K369A, K369A-F370W,
andR368A-K369A-F370W.B, PC3andC, DU145cell lysates fromcells eitheruntransfectedor transiently transfected
with either vector or wild type or mutant CDCP1-Flag expression constructs analyzed by anti-Flag Western blot
analysis. Anti-GAPDH Western blot analysis was performed to examine protein loading. Graphs were generated
from densitometric analysis of at least three separate experiments. For 70 and 135 kDa CDCP1 and GAPDH, signal
intensities from cells transfectedwithmutant constructs were normalized against the signal from cells transfected
withwild-type CDCP1. These normalized valueswere used to calculate the ratio of 70 to 135 kDa CDCP1.
FIGURE 5. The CDCP1 ectodomain is shed intact from the cell surface.West-
ern blot analyses using a goat antibody generated against the extracellular
domain of CDCP1 (R&DSystemsAF2666).A, analysis of lysates fromprostate cell
lines passagedwith EDTA demonstrating that this antibody recognizes 135 kDa
but not 70 kDaCDCP1 indicating that the cognate antigen is located in the shed
portion of CDCP1. B, analysis of conditioned media from these cell lines. Cells
were cultured in serum-free medium for 3 days. The medium was then centri-
fuged briefly to remove intact cells, and proteins were recovered by acetone
precipitation. C, analysis of serum-free conditioned media from HeLa cells tran-
siently transfected with expression constructs encoding CDCP1 truncated after
either Arg-368 (designated R368*) or Lys-369 (K370*).
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ysis is a driver of phosphorylation of 70 kDa CDCP1 and for-
mation of the 70 kDa p-CDCP1SrcPKC complex. To exam-
ine this question, we performed anti-CDCP1 antibody
immunoprecipitations from 22Rv1 cells treated with DU145-
conditioned medium (which cleaves after both Arg-368 and
Lys-369 converting CDCP1 to 70 kDa). To ensure that any
effects were due to proteolytic activity, we included a control
experiment in which DU145medium had been pretreated with
protease inhibitor mixture before incubation with 22Rv1 cells.
As CDCP1 contains five intracellular tyrosine residues (Tyr-
707, Tyr-734, Tyr-743, Tyr-762, Tyr-806), to examine the total
tyrosine phosphorylation state of CDCP1, rather than onlyTyr-
734, Western blot analyses were performed with anti-p-tyro-
sine antibody PY20, as well as with anti-Src, -PKC, and
-CDCP1 antibodies.
Significantly, as shown in Fig. 7C, Western blot analysis indi-
cated that DU145medium induced complete conversion of 135
kDa CDCP1 to 70 kDa (bottom panel), which was accompanied
by tyrosine phosphorylation of 70 kDa CDCP1 (upper panel),
and binding of PKC (second panel from top) and Src (second
panel from bottom). Importantly, the 70 kDa p-CDCP1
SrcPKC complexwas not detected in the absence of phospha-
tase inhibitors (Fig. 7C, lane 4), indicating that proteolysis-in-
duced formation of this complex is dependent on phosphory-
lation. Similarly, data obtained in the presence of protease
inhibitors (Fig. 7C, lane 5) indicated that formation of this com-
plex is dependent on proteolytic activity and not some other
factor present in DU145 media. In all experiments, DU145
medium treatment had no effect on cell adhesion (data not
shown).
As DU145medium cleaves CDCP1 at both Arg-368 and Lys-
369, we were interested to examine the effect of proteolysis at
Arg-368 only. For this purpose we performed a time course
treatment of 22Rv1 cells with recombinant matriptase, which
wehave shown cleavesCDCP1 exclusively at this site. As shown
in Fig. 8A, matriptase (20 nM) induced tyrosine phosphoryla-
tion of 70 kDa CDCP1 in 22Rv1 cells within 30 min. However,
in contrast to an equal concentration of trypsin, which induced
complete detachment of cells in 10 min (data not shown),
matriptase had no impact on 22Rv1 cell attachment after 2 h of
treatment (Fig. 8B). As shown in Fig. 8C, after 30 min
matriptase completely converted CDCP1 to 70 kDa and, like
DU145medium, this was accompanied by tyrosine phosphory-
lation of 70 kDa CDCP1 and binding of Src and PKC. These
data indicate that cleavage at Arg-368 promotes formation of
the 70 kDa p-CDCP1SrcPKC complex.
DISCUSSION
CDCP1 is an integral membrane glycoprotein with potential
as a marker (1, 2, 5–9) and therapeutic target (10–13) for a
number of cancers. Currently its function and the mechanisms
regulating CDCP1 in cancer and normal physiology are not
known (14). Here we show that full-length, 135 kDa CDCP1 is
proteolytically processed in cultured cell lines by endogenous
FIGURE 6. The serine proteasematriptase is an efficient but not essential
processor of CDCP1. A, anti-FlagWestern blot analysis of lysates fromHeLa-
CDCP1-Flag cells either untreated () or incubated with 1, 5, or 10 nM
matriptase for 1, 5, 10 or 30min. B,Western blot analysis of lysates from22Rv1
cells either untreated () or incubated with 1, 5, or 10 nM matriptase for 1, 5,
10, or 30minusingagoat anti-CDCP1antibody (Abcamab1377). Anti-GAPDH
Western blot analysis was performed to examine protein loading. C, HeLa
cells were either untransfected, transfected with vector alone, or co-trans-
fectedwithmatriptase and eitherwild type (WT) CDCP1-Flag expression con-
struct or constructs encoding the indicated single anddouble residuemutant
CDCP1-Flag constructs or triple mutant CDCP1-Flag-R368A-K369A-F370W.
After 24 h, lysates were collected and analyzed by anti-Flag, anti-matriptase,
and anti-GAPDHWestern blot analysis. D, polyclonal populations of PC3 and
DU145 cells were stably transfected with one of four CDCP1 knockdown
miRNA constructs. After 4 weeks of selection in blasticidin, cell lysates were
analyzed by Western blot analysis using rabbit anti-matriptase, goat anti-
CDCP1 (Abcam ab1377), and anti-GAPDH antibodies.
Proteolytic Processing of CDCP1
AUGUST 20, 2010•VOLUME 285•NUMBER 34 JOURNAL OF BIOLOGICAL CHEMISTRY 26169
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
serine protease activity to a C-terminal 70 kDa fragment. We
also show for the first time that, independent of cell detach-
ment, proteolysis is accompanied by tyrosine phosphorylation
of 70 kDa CDCP1 and recruitment of Src and PKC to this
cell-retained fragment. Importantly, examination of condi-
tioned medium indicates that proteolytic processing also gen-
erates a shed 65 kDa N-terminal CDCP1 ectodomain. Our
detection of this CDCP1 fragment in conditioned medium by
Western blot analysis is consistent with our previous immuno-
histochemical detection of soluble CDCP1 in vivo within the
lumen of normal colonic crypts and colon adenocarcinoma (2).
These data provide support for the proposal that soluble/shed
CDCP1may be useful as amarker for diseases in which CDCP1
processing is dysregulated (2).
Our data raise the possibility that proteolytic processing of
CDCP1 establishes two cellular signaling pathways. One
involving the direct relay of signals across the plasma mem-
brane via the CDCP1 70 kDa cell-retained C-terminal region.
As shown in Fig. 9, in this pathway
proteolysis induces tyrosine phos-
phorylation of 70 kDa CDCP1 and
recruitment of Src and PKC to
this fragment forming a 70 kDa
p-CDCP1SrcPKC complex. As
previous reports suggest that phos-
phorylation of CDCP1 and forma-
tion of CDCP1 signaling complexes
are important in a number of set-
tings, it is likely that proteolytically
induced formation of the 70 kDa
p-CDCP1SrcPKC complex seen
by us will also be functionally
important. For example, Uekita et
al. (10) demonstrated that PKC,
phosphorylated by a CDCP1SFK
complex, is essential for CDCP1-
mediated A549 lung cancer cell
resistance to anoikis. Furthermore,
135 kDa p-CDCP1-Y734 levels were
increased in gastric cancer 44As3
tumor nodules in nude mice com-
pared with these cells grown in cul-
ture and p-CDCP1-Y734 levelswere
elevated in 30% of 10 analyzed
scirrhous-type gastric cancer tissues
compared with normal tissue (11).
In addition, phosphorylation of
CDCP1 at Tyr-743, while rare in
normal epithelium, is a common
event in many cancers of epithelial
origin and has been proposed to be
of importance in invasion and
metastasis of these malignancies
(16). In addition, phosphorylation
of 70 kDa CDCP1 has been noted in
trypsin induced cell rounding and
detachment (3, 17) and is a conse-
quence of loss of cell anchorage
common to events such as mitosis and physiological cell shed-
ding occurring at the apices of colonic villi (17).
As shown in Fig. 9, we are also proposing that proteolytic
processing of CDCP1 may initiate a second signaling pathway
via the shed CDCP1 65 kDa ectodomain. It is possible that this
domain may act as a ligand either inducing cell signaling by
binding to a plasma membrane receptor or modulating signal-
ing by functioning as a competitive inhibitor for a receptor.
Alternatively, it may function as amatrix interacting protein. In
this capacity modulating cell:matrix interactions occurring via
known CDCP1 interacting proteins such as syndecan 1 and 4
(4) and the integrin binding tetraspannin CD9 (35) (Fig. 9).
The work reported here clarifies data from a number of
recent reports on CDCP1 species of different apparent molec-
ular weights. Specifically, it has previously been demonstrated
that CDCP1 is expressedwith a reportedmolecularmass of 135
or 140 kDa (2–4, 10, 15) and as shorter species variously
described as 70, 80, or 85 kDa that are expressed endogenously
FIGURE 7. Examination of tyrosine phosphorylation of CDCP1 and binding of Src and PKC induced by
DU145 media. A, anti-Src, -PKC, -p-CDCP1-Y734 (performed with an antibody that detects both p-CDCP1-
Y734 and p-FAK-Y861), and -CDCP1 (CST 4115) Western blot analysis of anti-CDCP1 immunoprecipitates (CST
4115) obtained fromDU145 cells. B, anti-CDCP1 (CST 4115), -p-CDCP1-Y734 (performedwith an antibody that
detects both p-CDCP1-Y734 and p-FAK-Y861), -PKC, and -Src Western blot analysis of anti-Src immunopre-
cipitates obtained from DU145 cells. C, anti-phosphotyrosine, anti-PKC, anti-Src, and anti-CDCP1 (CST 4115)
Western blot analysis of anti-CDCP1 immunoprecipitates obtained from 22Rv1 cells either untreated () or
treated () with 3 day serum-free conditioned medium from DU145 cells for 36 h. The media was either
untreated () or treated () with protease inhibitor (PI) mixture before incubation with 22Rv1 cells. Lysates
from all experiments were collected in the presence () or absence () of sodium vanadate and sodium
fluoride. All experiments included control immunoprecipitations performed with species matched IgG. NS,
nonspecific.
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or induced through the action of exogenous serine proteases
such as trypsin and plasmin (3, 10, 11, 16, 17). By analyzing cell
lines exclusively passaged non-enzymatically, we show that
the short endogenously expressed CDCP1 protein has amolec-
ular mass of 70 kDa. We have also shown that trypsin and
another serine protease, matriptase, generate CDCP1 of the
same molecular mass (70 kDa).
The difference in molecular mass
reported by us for low molecular
mass CDCP1 (70 kDa) and previ-
ously reported assignments of 80
and 85 kDa is likely due to the use
of different molecular weight
standards for protein sizing or
possibly due to differential glyco-
sylation or other post-transla-
tional modifications.
A significant finding from this
study, obtained through immuno-
purification of 70 kDa CDCP1,
N-terminal sequencing, and muta-
genesis, is that proteolytic process-
ing of this integral membrane pro-
tein occurs at adjacent sites,
Arg-368 and Lys-369. These sites
are located between two regions of
unknown function that have low
homology to CUB domains and
span residues 221–348 and 417–
544, respectively (14). Based upon
the high degree of variation in
sequence either side of Arg-368
and Lys-369 (KQSR2KFVP and
QSRK2FVPG; arrow indicates cleavage site), we propose that
processing at these sites is mediated by different serine pro-
teases. This proposal is supported by our mutagenesis studies
showing that for cleavage atArg-368, the residues located in the
P1 (Lys-369) and P2 (Phe-370) positions are important, while
for cleavage at Lys-369 the P2 (Arg-368) position is important.
Althoughwe have shown that the proteolytic activity present in
DU145, which cleaves at both Arg-368 and Lys-369, and the
serine protease matriptase, which cleaves exclusively at Arg-
368, both induce phosphorylation of 70 kDa CDCP1 and
recruitment of Src and PKC, an interesting possibility is that
cleavage at these two sites will induce different cellular
responses via activation of different signaling pathways and
release of ectodomains that differ by one residue at the C
terminus.
Another interesting observation was our finding that the
membrane-anchored and cell surface-shed serine protease
matriptase is an efficient but not essential processor of CDCP1.
Our finding that cleavage occurs at Arg-368 is supported by
Bhatt et al. (4) who previously showed that the recombinant
serine protease domain of matriptase, is able to cleave the puri-
fied recombinant extracellular domain of CDCP1 at this site in
vitro. However, it is clear from our experiments using four dif-
ferent silencing constructs in two prostate cancer cell lines that
reduction of matriptase expression does not reduce CDCP1
processing. What is not yet clear is whether endogenous
matriptase cleaves CDCP1 in cultured cells or in vivo.
A possibility is that even though we reduced matriptase pro-
tein levels by up to 90%, this was not sufficient to reduce
CDCP1 processing in PC3 and DU145 cells at Arg-368. Of rel-
evance, it has previously been shown that, whereas deletion of
FIGURE 8.Matriptase proteolysismediates tyrosine phosphorylation and binding of Src and PKC to 70
kDa CDCP1. A, anti-phosphotyrosine Western blot analysis of proteins immunoprecipitated from 22Rv1 cell
lysatesusinga rabbit anti-CDCP1antibody (CST4115). Lysateswere collected from22Rv1cells eitheruntreated
() or treated () with 20 nM matriptase for the indicated times. The blot was reprobed with an anti-rabbit
secondary antibody to detect rabbit IgG to assess consistency in the amount of antibody used for immuno-
precipitations. B, photographic images of 22Rv1 cells either untreated (left panel) or treated for 2 h with 20 nM
matriptase (right panel). Bar, 50m. C, anti-phosphotyrosine, -PKC, -Src, and -CDCP1 (CST 4115)Western blot
analysis of anti-CDCP1 (CST 4115) immunoprecipitates obtained from 22Rv1 cells either untreated () or
treated () withmatriptase (20 nM; 0.5 h). Lysates were collected in the presence () or absence () of sodium
vanadate and sodium fluoride. All experiments included control immunoprecipitations performed with spe-
cies matched IgG. NS, nonspecific.
FIGURE9.Protease-mediatedprocessingofCDCP1.Serineproteolysis gen-
erates a 65 kDa shedectodomain anda tyrosine-phosphorylated cell retained
70 kDa CDCP1 fragment. Proteolysis occurs at Arg-368 and Lys-369 between
CUB-like domain 1 and 2 of CDCP1 (the 3 CDCP1 CUB-like domains are shown
asblue ovals). Proteolysis results in tyrosinephosphorylationof 70 kDaCDCP1
(yellow-filled circles) and recruitmentof Src andPKC in aphosphorylation-de-
pendentmanner. We propose that the CDCP1 ectodomainmay function as a
ligand or competitive inhibitor for a cell surface receptor (autocrine receptor
binding is shown, but paracrine and endocrine signaling may also be rele-
vant) or as a matrix-interacting protein potentially modulating cell:matrix
interactions occurring via known CDCP1 interacting proteins such as synde-
can 1 and 4 and the tetraspannin CD9 (dotted arrows). Potential signaling
downstream of the 70 kDa CDCP1 cell-retained fragment and ectodomain
resulting in direct cellular responses and changes in gene expression are rep-
resented by curved and straight arrows, respectively. Currently the endoge-
nous serine protease or proteases mediating cleavage of CDCP1 at Arg-368
andLys-369arenot known.However,wehave shown that the cell surfaceand
shed serine protease matriptase efficiently cleaves CDCP1 exclusively at
Arg-368.
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thematriptase gene inmice results in neonatal death due to loss
of epidermal and oral barrier function (36), hypomorphicmice,
expressing matriptase mRNA at1% of the levels seen in wild-
type mice, survive normally with only a moderately impaired
skin barrier function (37). Although this suggests that
matriptase-mediated proteolysis must be completely reduced
to block its normal role in maintenance of skin function, it is
important to note that this study from List et al. (37) was not
able to quantitatively measure residual matriptase proteolytic
activity. Therefore it is possible that matriptase proteolytic
activity in these hypomorphic mice was relatively high despite
low mRNA levels.
We also note that if our proposal is correct that cleavage at
Arg-368 and Lys-369 requires the action of two different serine
proteases, silencing of one of these enzymes would not be
expected to prevent CDCP1 processing, as cleavage at the sec-
ond site would still occur. Accordingly, it remains feasible that
matriptase is involved in CDCP1 processing in cells and in vivo,
and it will not be practical to address this question further until
it is possible to silence bothmatriptase and proteases capable of
cleaving CDCP1 at Lys-369. Further, we note that there is addi-
tional published data supporting the proposal thatmatriptase is
a relevant processor of CDCP1 at Arg-369. For example, Bhatt
et al. (4) demonstrated that matriptase and CDCP1 co-immu-
noprecipitate fromMDA-MB-468 breast cancer cells inducibly
overexpressing CDCP1. This observation is supported by our
immunoprecipitations showing that endogenous 135 kDa (but
not 70 kDa) CDCP1 and matriptase co-immunoprecipitate
from PC3 cells suggesting that these proteins interact via the
shed CDCP1 fragment (residues 30–368) (supplemental
Fig. S1). The existence of interactions between CDCP1 and
matriptase is also supported by a recent report showing that
these proteins co-immunoprecipitate from SW480 and SW620
colon cancer cell lysates using an antibody against the tet-
raspanin CD9 (35). In addition, it has been reported that the
mRNA expression patterns of this protease:substrate pair are
significantly correlated in many tissue types (38). It has also
been shown in separate reports that both matriptase (39) and
CDCP1 (12) are expressed during prostate cancer progression.
In particular, as it is known that matriptase expression
increases with increasing prostate cancer grade, with concom-
itant reduction in expression of its cognate inhibitor, hepato-
cyte growth factor activator inhibitor-1 (HAI-1) (39), it is pos-
sible that increased matriptase activity will result in increased
CDCP1 processing during prostate cancer progression. Fur-
thermore, it has been recognized that the residues N terminus
to the CDCP1 R368 cleavage site (KQSR) match exactly with
the peptide substrate specificity ofmatriptase determinedusing
a positional scanning-synthetic combinatorial library approach
(40). Finally, it has been shown that the trypsin-fold serine pro-
tease inhibitor ecotin, at 7 M, markedly reduced processing in
MDA-MB-468 cells stably overexpressing CDCP1 (4). These
findings suggest that although matriptase silencing does not
reduce proteolytic processing of CDCP1 in PC3 and DU145
cells, it is possible that matriptase cleavage of CDCP1 at Arg-
368 may be relevant in pathological and physiological settings.
Based on our data it will be important to identify the endog-
enous serine proteases that cleave CDCP1 in normal and path-
ological settings. For example, it appears likely that loss of reg-
ulation of these proteases will lead to increased processing of
CDCP1 and inappropriate amplification of downstream signal-
ing (including recruitment of Src and PKC), potentially lead-
ing to cellular responses critical for disease progression. In
addition to matriptase, plasmin, and trypsin, candidate pro-
teases include secreted and shed members of the proprotein
convertase family as these proteases cleave after arginine or
lysine, preceded by a basic residue at the P2, P4, P6, and/or
P8-position (41). Other candidates include the sheddases
ADAM10 and ADAM17, which process a number of other cell
surface proteins after basic residues (42) and the TTSP hepsin,
which is structurally related to matriptase (43), has preference
for cleavage after arginine/lysine residues (44), and is up-regu-
lated in (45, 46) and proposed to promote prostate cancer pro-
gression (46–48).
Of relevance, it is clear from our inhibitor profile, that serine
proteases mediating cleavage of CDCP1 at both Arg-368 and
Lys-369 are sensitive to the serine protease inhibitor aprotinin
( 5 M), with lower sensitivity to another serine protease
inhibitor PMSF ( 2 mM) and the mixed serine/cysteine prote-
ase inhibitor leupeptin ( 50 M). Although not completely
analogous to inhibition of cleavage of macromolecular sub-
strates such as CDCP1, the inhibitor profiles of matriptase
and hepsin against a fluorogenic tripeptide substrate (QAR)
overlap our observations of inhibition of CDCP1 processing
suggesting that these proteases may be cellular processors of
this cell surface protein-0.3 M aprotinin and 1 M leupeptin
inhibit the activity of both proteases against this tripeptide
substrate (49). In addition, significantly hepsin cleavage of
the macromolecular substrate factor VII is inhibited by 8 M
aprotinin (50).
In summary, we have identified two residues, Arg-368 and
Lys-369, as sites at which the integral membrane protein
CDCP1 is proteolytically processed in cells. We have also
shown that proteolysis induces recruitment of Src and PKC to
tyrosine-phosphorylated 70 kDa CDCP1. These data provide a
platform for further studies examining the biological function,
molecular regulators, and downstream signaling events cou-
pled to proteolytic processing of CDCP1 and whether these
contribute to disease progression. Also, the observation that
low and highmolecular weight CDCP1 species are expressed in
neonatal mouse epidermis (3), indicates that it will be impor-
tant to understand mechanisms regulating CDCP1 processing
in normal physiological settings.
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